Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, email us.
RESEARCH TRIANGLE PARK, N.C. , May 08, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the first quarter ended March 31, 2018 . “We are off to a strong start in 2018 as we continue to make progress advancing all our HAE development
RESEARCH TRIANGLE PARK, N.C. , May 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the European Medicines Agency (EMA) has approved peramivir
Questions about stock transfers and lost certificates should be directed to the transfer agent: American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
1-800-937-5449 (toll free in US and Canada)
1-718-921-8200 (callers outside the US and Canada)